CARsgen Therapeutics of Shanghai reported positive data from a China investigator-initiated trial of its Claudin18.2 CAR-T therapy in patients with digestive system tumors. In 36 patients who had previously been heavily pre-treated, CT041 produced an overall response rate of 48.6% and a disease control rate of 73.0%. This compares to a historical efficacy rate of 4% to 8% from chemotherapy and 11% for an anti-PD-1 antibody. CT041 is the only Claudin18.2 CAR-T in China and US clinical trials. More details.... Stock Symbol: (HK: 2171) Share this with colleagues: // //